Dexcom (DXCM) | Stock Overview & Key Data
Dexcom Performance Comparison
Stock Range
Today's Range
Low: $80.29
High: $82.04
on August 15, 2025
52 Week Range
Low: $57.52
High: $93.25
on April 4, 2025
on February 18, 2025
All-Time High: $164.86 on November 15, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$31.4B
EPS
1.42
P/E Ratio (TTM)
56.46
Forward P/E
39.49
P/B Ratio
12.22
PEG Ratio
39.49
Div. Yield
N/A
ROE
22.83%
Beta
1.439
Debt to Equity
100.24
Financial Highlights
Profitability
Gross Margin
59.53%
Operating Margin
18.37%
Profit Margin
13.29%
Returns and Earnings
Return on Assets (TTM)
6.08%
Return on Equity (TTM)
22.83%
EBITDA
$1.0B
Net Income (TTM)
$571.5M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$11.01
Quarterly Revenue Growth (YoY)
15.20%
Quarterly Earnings Growth (YoY)
25.30%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Dexcom DXCM | 31.44B Large-cap | 2.65% | -4.52% | -5.51% | -10.58% | 3.12% | 8.44% | -4.89% | -24.15% |
| Abbott Laboratories ABT | 228.04B Mega-cap | -1.88% | 0.20% | -1.20% | 1.21% | 16.14% | 18.69% | 19.71% | 28.66% |
| Boston Scientific BSX | 152.25B Large-cap | 0.03% | -0.30% | -1.61% | -2.07% | 15.43% | 31.85% | 145.53% | 168.46% |
| Stryker SYK | 144.40B Large-cap | 1.13% | -2.24% | -2.64% | -0.98% | 6.44% | 13.03% | 75.08% | 102.30% |
| Medtronic plc MDT | 118.98B Large-cap | 0.15% | 4.26% | 8.02% | 8.07% | 15.96% | 9.95% | -2.08% | -5.78% |
| Edwards Lifesciences EW | 45.61B Large-cap | -0.11% | 1.89% | 1.80% | 3.42% | 7.81% | 13.55% | -20.59% | -0.57% |
Ownership & Short Interest
Insider Ownership
0.42%
Institutional Ownership
99.31%
Shares Short
8M
Short Ratio
2.71
Short % of Shares Outstanding
2.77%
Average 10-Day Volume
5M
Average 90-Day Volume
4M
Dexcom Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Dexcom would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is DXCM's 52-week high and low?
- In the last 52 weeks, Dexcom reached a high of $93.25 (on February 18, 2025) and a low of $57.52 (on April 4, 2025).
- What is the market cap and P/E ratio for DXCM?
- Curious about Dexcom's size and valuation? Its market capitalization stands at 31.44B. When it comes to valuation, the P/E ratio (trailing twelve months) is 56.46, and the forward P/E (looking ahead) is 39.49.
- Does DXCM pay dividends? If so, what's the yield?
- As for dividends, Dexcom isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Dexcom's main competitors or similar companies to consider before investing?
When looking at Dexcom, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abbott Laboratories
ABT228.04B Healthcare Medical Devices 18.69% 19.71% Boston Scientific
BSX152.25B Healthcare Medical Devices 31.85% 145.53% Stryker
SYK144.40B Healthcare Medical Devices 13.03% 75.08% Medtronic plc
MDT118.98B Healthcare Medical Devices 9.95% -2.08% Edwards Lifesciences
EW45.61B Healthcare Medical Devices 13.55% -20.59% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Dexcom Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Dexcom's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 22.83%, the Debt to Equity ratio from the most recent quarter is 100.24, and its Gross Profit Margin stands at 59.53%.
- What is the recent revenue and earnings growth for DXCM?
- Looking at Dexcom's growth, its revenue over the trailing twelve months (TTM) was $4B. Compared to the same quarter last year (YoY), quarterly revenue grew by 15.20%, and quarterly earnings saw a YoY growth of 25.30%.
- How much of DXCM stock is held by insiders and institutions?
- Wondering who owns Dexcom stock? Company insiders (like executives and directors) hold about 0.42% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 99.31%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.